Bendamustine and its role in the treatment of unfit patients with chronic lymphocytic leukaemia: a perspective review.

about

Efficacy and safety of B-cell receptor signaling pathway inhibitors in relapsed/refractory chronic lymphocytic leukemia: a systematic review and meta-analysis of randomized clinical trials.

P2860

Q50166015-533787CD-99FE-47F2-87FA-0BBA80244C01

P2860

Bendamustine and its role in the treatment of unfit patients with chronic lymphocytic leukaemia: a perspective review.

Item

http://www.wikidata.org/entity/Q38676408

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Bendamustine and its role in t ...... ukaemia: a perspective review.

@en

type

Item

label

Bendamustine and its role in t ...... ukaemia: a perspective review.

@en

prefLabel

Bendamustine and its role in t ...... ukaemia: a perspective review.

@en

P1476

Bendamustine and its role in t ...... ukaemia: a perspective review.

@en

P2093

Natali Pflug

http://www.w3.org/2001/XMLSchema#string

Othman Al-Sawaf

http://www.w3.org/2001/XMLSchema#string

Paula Cramer

http://www.w3.org/2001/XMLSchema#string

Valentin Goede

http://www.w3.org/2001/XMLSchema#string

P2860

Routine treatment of patients with chronic lymphocytic leukaemia by office-based haematologists in Germany-data from the Prospective Tumour Registry Lymphatic Neoplasms.

Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia.

Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group.

Bendamustine plus mitoxantrone for relapsed/refractory chronic lymphocytic leukaemia (CLL): results of a multicentre phase II study of the German CLL Study Group (GCLLSG).

Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group.

The combination of rituximab, bendamustine, and cytarabine for heavily pretreated relapsed/refractory cytogenetically high-risk patients with chronic lymphocytic leukemia.

Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.

Interactions between comorbidity and treatment of chronic lymphocytic leukemia: results of German Chronic Lymphocytic Leukemia Study Group trials.

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.

Bendamustine: mechanism of action and clinical data.

P304

197-205

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/2040620717699365

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Michael Hallek

Othman Al-Sawaf

Valentin Goede

P577

2017-03-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28567239

http://www.w3.org/2001/XMLSchema#string

P921

lymphocyte

P932

5424860

http://www.w3.org/2001/XMLSchema#string

Bendamustine and its role in the treatment of unfit patients with chronic lymphocytic leukaemia: a perspective review.

about

P2860

P2860

Bendamustine and its role in the treatment of unfit patients with chronic lymphocytic leukaemia: a perspective review.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932